

## REMARKS

The Examiner has rejected Claims 20-25 under 35 U.S.C. 112, second paragraph, as being indefinite. The Examiner states that the term "crystallizing" in claim 20 is unclear.

In response, applicants have canceled Claims 1, 2, 12, and 20-25, and added new Claims 26-36, in order to more clearly set forth applicants' invention and remove the term "crystallizing".

Applicants' new Claims 26-29 correspond to canceled Claims 1, 2, and 12 with the exception that in the mixture of diastereoisomers of a compound of Formula I, the ratio of  $B/(A+B)$  has been broadened to 0.4 to 0.7. Support is found in the specification, as originally filed, on page 2, line 17, and on page 5, line 9.

Applicants' new Claims 30-36 correspond to canceled Claims 20-25 with the exception that the ratio of  $B/(A+B)$  has been broadened to 0.4 to 0.7, as noted above, and a list of nitriles and ketones has been provided. Support is found in the specification, as originally filed, on page 4, lines 20-22.

A two-month extension is hereby requested pursuant to 37 CFR §1.136(a). Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$420.00 for payment of the extension fee. An Additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees under 37 CFR §1.17 which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Respectfully submitted,

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 430  
East Hanover, NJ 07936-1080  
(862) 778-7945

  
John D. Thallemer  
Attorney for Applicants  
Reg. No. 34,940

Date: April 26, 2004